Pieris Pharma (PIRS) Reports In-Line Q2 Loss

Pieris Pharma (NASDAQ: PIRS) reported Q2 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $1.07 million versus the consensus estimate of $300 thousand.

For earnings history and earnings-related data on Pieris Pharma (PIRS) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Palo Alto Networks (PANW) PT Raised to $400 at TD Cowen
• Allogene (ALLO) Reiterated at Market Outperform by Citizens: 'ALPHA3 Trial is On-Track'